Form 4: Spike Loy Acquires MoonLake Immunotherapeutics Options

Director Spike Loy of MoonLake Immunotherapeutics acquired options to purchase 22,195 Class A ordinary shares, with vesting contingent on continued service.

Summary

• Spike Loy, a Director at MoonLake Immunotherapeutics, has acquired options to purchase 22,195 Class A ordinary shares.
• The options have an exercise price of $19.19 and an expiration date of June 17, 2036.
• These options will vest in full on the earlier of June 17, 2027, or the date of the Issuer's next annual general meeting, provided Loy continues to serve the company.
• The transaction was reported on June 18, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating director confidence through option acquisition, but without immediate financial impact or new strategic information.

Positives

• Director Spike Loy's acquisition of options signals continued commitment and potential future stake in the company.
• The vesting schedule aligns with continued service, incentivizing long-term engagement.

Future Outlook

The acquisition of options by a director suggests a positive outlook from management regarding the company's future prospects, as options typically gain value if the stock price increases.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology and pharmaceutical sectors, aligning management incentives with shareholder value creation, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as a sign of confidence in the company's future performance, potentially aligning director interests with those of shareholders.

Next Steps

• Spike Loy's continued service to MoonLake Immunotherapeutics.
• Vesting of stock options on the earlier of June 17, 2027, or the next annual general meeting.

Key Dates

Keywords

MoonLake Immunotherapeutics, MLTX, Spike Loy, Director, Stock Options, Beneficial Ownership, SEC Form 4